---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062046"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:48:18.231322+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics Q3 net loss $16.7M; epetraborole Phase 3 enrollment underway

## Summary
- Net loss $16.7M for Q3 2023, up from $11.3M in Q3 2022; R&D and G&A expenses increased.
- Cash and investments $150.2M at Sept 30; $70M raised in August stock offering; cash runway through summer 2025.
- Phase 3 part of pivotal epetraborole trial in refractory MAC lung disease initiated; Phase 2 top-line data expected summer 2024.
- Received Bill & Melinda Gates Foundation grant for TB/malaria; exclusive license for Chagas disease candidate AN2-502998.

## SEC filing metadata
- accession: 0000950170-23-062046
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000095017023062046/0000950170-23-062046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000095017023062046/antx-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062046
- JSON: https://secwatch.observer/filing/0000950170-23-062046.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062046.txt

## Key facts
- Earnings Releases
  AN2 Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income Net loss was $16.7 million.
  - Period: third quarter ended September 30, 2023
  - Net income: Net loss was $16.7 million
  - Result: reported results
  source text: On November 9, 2023, AN2 Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1880438/000095017023062046/0000950170-23-062046-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.